Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Boye

Showing results (171-180 of 190) with videos related to

Pageof 19
Sort By:
Plos One|March 28, 2014
Natural history of cone disease in the murine model of Leber congenital amaurosis due to CEP290 mutation: determining the timing and expectation of therapyShannon E Boye, Wei-Chieh Huang, Alejandro J Roman, et al.
Plos One|May 3, 2013
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectorsChristine N Kay, Renee C Ryals, George V Aslanidi, et al.
Human Gene Therapy|August 1, 2012
The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retinaShannon E Boye, John J Alexander, Sanford L Boye, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 19, 2020
Novel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene TherapySanford L Boye, Shreyasi Choudhury, Sean Crosson, et al.
Human Molecular Genetics|August 28, 2015
Intravitreal delivery of a novel AAV vector targets ON bipolar cells and restores visual function in a mouse model of complete congenital stationary night blindnessMiranda L Scalabrino, Sanford L Boye, Kathryn M H Fransen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2011
Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindnessM Mehdi Doroudchi, Kenneth P Greenberg, Jianwen Liu, et al.
Human Gene Therapy. Clinical Development|May 23, 2013
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosaThomas J Conlon, Wen-Tao Deng, Kirsten Erger, et al.
Human Gene Therapy|December 6, 2012
AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosisSanford L Boye, Igor V Peshenko, Wei Chieh Huang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2025
A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMDLynn J A Ebner, Cornelia Imsand, Duygu Karademir, et al.
Iscience|May 17, 2021
Safety and improved efficacy signals following gene therapy in childhood blindness caused by <i>GUCY2D</i> mutationsSamuel G Jacobson, Artur V Cideciyan, Allen C Ho, et al.
Pageof 19

Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
Plos One|March 28, 2014
Natural history of cone disease in the murine model of Leber congenital amaurosis due to CEP290 mutation: determining the timing and expectation of therapyShannon E Boye, Wei-Chieh Huang, Alejandro J Roman, et al.
Plos One|May 3, 2013
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectorsChristine N Kay, Renee C Ryals, George V Aslanidi, et al.
Human Gene Therapy|August 1, 2012
The human rhodopsin kinase promoter in an AAV5 vector confers rod- and cone-specific expression in the primate retinaShannon E Boye, John J Alexander, Sanford L Boye, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 19, 2020
Novel AAV44.9-Based Vectors Display Exceptional Characteristics for Retinal Gene TherapySanford L Boye, Shreyasi Choudhury, Sean Crosson, et al.
Human Molecular Genetics|August 28, 2015
Intravitreal delivery of a novel AAV vector targets ON bipolar cells and restores visual function in a mouse model of complete congenital stationary night blindnessMiranda L Scalabrino, Sanford L Boye, Kathryn M H Fransen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 21, 2011
Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindnessM Mehdi Doroudchi, Kenneth P Greenberg, Jianwen Liu, et al.
Human Gene Therapy. Clinical Development|May 23, 2013
Preclinical potency and safety studies of an AAV2-mediated gene therapy vector for the treatment of MERTK associated retinitis pigmentosaThomas J Conlon, Wen-Tao Deng, Kirsten Erger, et al.
Human Gene Therapy|December 6, 2012
AAV-mediated gene therapy in the guanylate cyclase (RetGC1/RetGC2) double knockout mouse model of Leber congenital amaurosisSanford L Boye, Igor V Peshenko, Wei Chieh Huang, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 29, 2025
A novel multiplex RNAi therapy simultaneously targets Hif1a and Hif2a to defy retinal degeneration in two models of AMDLynn J A Ebner, Cornelia Imsand, Duygu Karademir, et al.
Iscience|May 17, 2021
Safety and improved efficacy signals following gene therapy in childhood blindness caused by <i>GUCY2D</i> mutationsSamuel G Jacobson, Artur V Cideciyan, Allen C Ho, et al.
Pageof 19